Eiken Chemical Of Japan Aims To Become Global Testing Agent Maker With ¥30 Billion In Sales
This article was originally published in PharmAsia News
Japanese diagnostic and testing agent maker Eiken Chemical announced April 28 plans to achieve ¥30 billion in sales in three to four years, and increase overseas sales from current 5 percent to 10 percent. For fiscal year 2009, the company estimated 2.6 percent increase in sales, reaching ¥26.7 billion. Eiken plans to expand markets for major products such as fecal occult blood and bacterial testing agents, urine testing paper, and develop new products based on loop-mediated isothermal amplification methods. Two such new products, Legionella and Mycoplasma pneumonia testing agents are under approval review in Japan. The company plans to launch them in September. In overseas market, Eiken unveiled an ambitious goal of ¥1.8 billion in sales for 2009, a 21 percent increase. (Click here for more - Japanese language
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.